Omontys approved for anemic people with kidney disease

(HealthDay) -- Omontys (peginesatide) has been approved by the U.S. Food and Drug Administration to treat anemia in adults who require dialysis due to chronic kidney disease.

Anemia is characterized by a lack of enough healthy . The newly approved drug is designed to stimulate bone marrow to produce more of these cells, reducing a person's need for a blood transfusion, the FDA said Tuesday in a news release.

Clinical testing of the once-monthly injection involved 1,608 people with abnormally low hemoglobin, a measure of anemia. The most common side effects were diarrhea, vomiting, high blood pressure and pain in the joints, back, legs or arms, the agency said.

Omontys should not be used in people with who are not on dialysis, nor those with cancer-related anemia, the FDA warned. It should also not be used as a substitute in people who require an immediate to treat anemia.

Omontys is marketed by Palo Alto, Calif.-based Affymax Inc.

More information: The U.S. National Library of Medicine has more about anemia.

add to favorites email to friend print save as pdf

Related Stories

Anemia drug not helpful for kidney disease patients

Dec 22, 2009

An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising.

FDA recommends lower doses of anemia drugs

Jun 24, 2011

(AP) -- Food and Drug Administration officials say doctors should use lower doses of anemia drugs when treating patients with failing kidneys due to the increased risk of stroke, blood clots and death.

Recommended for you

Sickle cell trait tied to increased pulmonary embolism risk

11 hours ago

(HealthDay)—For African-Americans, sickle cell trait is associated with an increased risk of pulmonary embolism, but not deep vein thrombosis, according to a study published online Nov. 13 in the Journal of Thrombosis an ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.